Cita APA

Chaft, J. E., Oxnard, G. R., Sima, C. S., Kris, M. G., Miller, V. A., & Riely, G. J. (2011). Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib – implications for clinical trial design.

Chicago Style Citation

Chaft, Jamie E., Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, i Gregory J. Riely. Disease Flare After Tyrosine Kinase Inhibitor Discontinuation in Patients With EGFR-mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib – Implications for Clinical Trial Design. 2011.

Cita MLA

Chaft, Jamie E., et al. Disease Flare After Tyrosine Kinase Inhibitor Discontinuation in Patients With EGFR-mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib – Implications for Clinical Trial Design. 2011.